Share tips 2025: this week’s top picks

If you’ve been keeping a close eye on share tips 2025, then don’t miss this weekly round-up of the top stocks to consider for your portfolio.

The MoneyWeek share tips 2025 guide pulls together some of the best stocks from some of the top share tipsters around.

As well as the UK financial pages, we look at publications across the pond for investors who want to diversify their holdings internationally.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

From Magnificent Seven, which are consistently among the world's most-bought stocks, to finding value in the FTSE 100, we look at where to invest this year.

This list is updated weekly.

Share tips 2025: top picks of the week

Four to buy

1. Wickes (LSE: WIX)
The Telegraph
DIY retailer Wickes is “finally in the money”, as recent glorious weather should have prompted more people to spruce up their gardens and homes. Following its post-Covid DIY hangover, Wickes has navigated tougher market conditions and shop refurbishments. It has also made itself more attractive to trade customers with a loyalty scheme. Improving household sentiment and a dip in house prices bode well. The stock’s valuation is “inexpensive”, and analysts expect higher profits and dividends in the coming years. 224p

2. Oxford Nanopore (LSE ONT)
This is Money
Oxford Nanopore’s sensing technology uses tiny holes and electric current to read the sequence of DNA and RNA. The stock’s performance since its flotation in 2021 has been “uninspiring”. Yet Oxford’s technology has broad uses, and if it can be used to read proteins, then the opportunity could be huge. The US government’s funding for health research remains uncertain, but a US company reportedly wants Nanopore’s technology, so “now might be a good time to snap up some shares”. 150p

3. Genus (LSE GNS)
Shares
Genus is on the cusp of fully commercialising its technology for making pigs resistant to the porcine reproductive and respiratory syndrome virus. The US has approved Genus’ technology, but approvals are still needed in other big markets. Analysts estimate that Genus has spent over £80 million developing the technology, with potential financial benefits expected from 2027. Genus uses a royalty-income model that provides stable revenue. 2,419p

4. Cake Box
Investors’ Chronicle
Cake Box recently bought Ambala Foods, a South Asian confectionery chain, for £22 million, £15.2 million of which was borrowed. Cake Box has introduced new ranges, is refreshing Ambala’s shops, and has started selling some of Ambala’s products within Cake Box shops. Although the acquisition increased debt, it could boost Cake Box’s earnings, with Panmure Liberum analysts lifting forecasts. It’s a “speculative buy”. 189p

One to sell

RM (LSE: RM)
Investors’ Chronicle
Education technology firm RM’s half-year losses narrowed despite revenue slipping amid a “tough UK schools market”. Sales at its education-resources arm and its IT software and bespoke services unit fell, while its exam software business increased sales and orders. RM swung to an adjusted operating profit from a loss last year. Yet the group’s debt has grown, and its banking facility prohibits dividends until the leverage ratio meets certain criteria. “We [will] wait to see what happens” over potential asset sales as part of RM’s plan to separate its three divisions, and progress on debt reduction, “before getting involved... Sell.” 99p

The rest...

1. Brickability (LSE: BRCK)
Investor's Chronicle
Brickability’s full-year like-for-like sales and adjusted earnings per share were broadly flat. Sales in the bricks and building materials division were steady owing to a weak building market. This division is set to improve as government policies encourage housebuilding. The brick merchant’s shift towards higher-margin specialist services has delivered significant earnings. The solar-panel business boosted revenue growth, and the cladding and fire remediation divisions should enjoy regulatory tailwinds. Analysts predict flat earnings this year, but a rise in 2027. Brickability’s valuation is “undemanding” and offers potential for “patient investors”. Buy (65p).

2. Personal Group (LSE: PGH)
Shares
Workplace benefits and health-insurance provider Personal Group is a minnow, but it has big ambitions. It aims for £100 million of sales by 2030, which could translate into £30 million of adjusted earnings, three times last year’s figure. It has built on its existing relationship with accounting software firm Sage and has many large clients. Personal Group has focused on securing recurring revenue streams and reducing the seasonality in the business while increasing dividends. Buy (298p).

3. Amgen (NASDAQ: AMGN)
The Telegraph
Amgen can weather challenges from the US government over drug pricing, tariffs, and Medicaid cuts. The US biotech company has paid dividend payouts for 13 consecutive years, and sales have reached $33.4 billion, thanks to its diverse range of 14 blockbuster drugs. Amgen plans to boost production of low-cost biosimilars to manage pricing pressures and healthcare costs. Top fund managers are excited by its obesity drug, MariTide. Buy ($297).

This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.